Timing and durability of response to erenumab in patients with chronic migraine.

Stewart J TepperSylvia LucasAnne Luise Haulund VollesenTodd J SchwedtJessica AilaniJames ScanlonJan KlattDenise E ChouAndrea WangGabriel Paiva da Silva Lima

Published in: Headache (2021)

A majority of erenumab-treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after ≥3 months of preventive treatment with erenumab in CM.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
combination therapy
machine learning
big data
patient reported outcomes
deep learning
data analysis